You are here » Home » Companies » Company Overview » Mavens Biotech Ltd

Mavens Biotech Ltd.

BSE: 590083 Sector: Others
NSE: N.A. ISIN Code: INE856C01047
BSE 00:00 | 04 Mar Mavens Biotech Ltd
NSE 05:30 | 01 Jan Mavens Biotech Ltd
OPEN 0.71
PREVIOUS CLOSE 0.74
VOLUME 25200
52-Week high 0.74
52-Week low 0.00
P/E
Mkt Cap.(Rs cr) 8
Buy Price 0.71
Buy Qty 4800.00
Sell Price 0.00
Sell Qty 0.00
OPEN 0.71
CLOSE 0.74
VOLUME 25200
52-Week high 0.74
52-Week low 0.00
P/E
Mkt Cap.(Rs cr) 8
Buy Price 0.71
Buy Qty 4800.00
Sell Price 0.00
Sell Qty 0.00

Mavens Biotech Ltd. (MAVENSBIOTECH) - Director Report

Company director report

Dear Members

The Board of Directors are pleased to present the 37th Annual Reporttogether with the Audited Financial Statement of Accounts and Auditor's Report of theCompany for the year ended 31st March 2019.

The Financial Highlights for the year under review are given below:

(Amt. in Rs.)
Particulars 31st March 2019 31st March 2018
Total Income 239744 2217000
Less: Expenses 22432654 5764988
Less: Exceptional Items 12380000 18373580
Profit/ -Loss before Taxation -34572910 -21921568
Less: Taxation -583575 -131656
Profit after Taxation -33989335 -21789912

Performance

The Total Income for the financial year under review is Rs. 239744/- against Rs.2217000/- in previous year. The Net Loss after taxation marked by the company during theyear under review was Rs. 33989335/- as compared to loss of Rs. 21789912/- duringthe previous year.

Compliance with the Indian Accounting Standards

As mandated by the Ministry of Corporate Affairs the financial statements for the yearended on March 31 2019 has been prepared in accordance with the Indian AccountingStandards (IND AS) notified under Section 133 of the Companies Act 2013 read with theRule 7 of Companies (Accounts) Rules 2014.

Operation

The Company has been continuously focusing on its existing line of business to improveits profitability in near future.

Dividend And Transfer To Reserve

Your Company intends to conserve available resources to invest in the growth of thebusiness and pursue strategic growth opportunities. Accordingly your Directors do notrecommend any dividend for the year. There has been no transfer to Reserves during theFinancial Year 2018-2019.

Change in The Nature Of Business

There is no change in the nature of business of the Company during the year underreview.

Public Deposits

The Company has not accepted or renewed any amount falling within the purview ofprovisions of section 73 of the Companies Act 2013 read with the Companies (Acceptance ofDeposit) Rules 2014 during the year under review. Hence the requirement for furnishingof details of deposits is not applicable.

Directors and Key Managerial Personnel (KMP)

As on March 31 2019 the Board of Directors of your Company comprised of Three (3)Directors All are Non-Executive and Independent directors.

During the year Ms. Kapila Tanwar (KMP) has tendered her resignation letter dated17/07/2018 to the board from the post of Company Secretary cum Compliance officer. TheBoard has considered and approved her resignation in their meeting held on 23/07/2018 withimmediate effect. The Board places on record its gratitude for the services rendered byher during the tenure as Company Secretary cum Compliance officer of the Company.

During the year Board of Directors have appointed Mr.Saurav Narang (ACS32813) asCompany Secretary in Whole-Time Employment with effect from 02nd January 2019 in duecompliance of Section 203 of the Companies Act 2013 read with Rule 8 of Companies(Appointment and Remuneration of Managerial Personnel) Rules 2014.

The Board also appointed Mr. Saurav Narang Company Secretary as Compliance Officer interms of Regulation 6(1) of SEBI (Listing Obligation and Disclosure Requirements)Regulation 2015.

The Board of Directors at their meeting held on 11/04/2019 appointed Mr. Kuldeep Doshias an Additional Director of Company. In the same meeting Board has appointed him asWhole Time Director of the Company for five consecutive years for a term upto 5 years i.e.10/04/2024 subject to approval of Shareholders at the ensuing Annual General Meeting andbased on the recommendations of the Nomination and Remuneration Committee on the termsand conditions set out in the draft agreement to be entered into with him.

Accordingly the Board of Directors of the Company (‘the Board') at their Meetingheld on Monday 29th July 2019 approved appointment of Mrs. Chanderkala Devi Lakhotia(DIN 06904489) as Additional Director u/s 161 of Companies Act 2013 under Non- ExecutiveIndependent Director category with effect from 25th July 2019 to hold office upto thedate of next Annual General Meeting and as Independent Director of the Company for aSecond term of 5 (Five) years w.e.f. 25th July 2019 subject to approval of the members ofthe company at the ensuing Annual General Meeting.

The resolution seeks the approval of members for the re-appointment of Mrs. ChanderkalaDevi Lakhotia as an Independent Director of the Company commencing from July 25 2019 upto July 24 2024 in terms of Section 149 and other applicable provisions of the Act andRules made there under. She is not liable to retire by rotation.

Appropriate resolutions for appointment /re-appointment are being placed for theapproval of the shareholders of the Company at the ensuing AGM. The brief resume ofdirectors appointed/re- appointed and other related information has been detailed in theNotice read along with the explanatory statement convening the 37th AGM of theCompany in accordance with the provisions of the Companies Act 2013 read with the Rulesissued there under and the Regulation 36 of SEBI (Listing Obligations and DisclosureRequirements) Regulations 2015 as amended from time to time.

Disclosure under Section 197(12) of the Companies Act 2013

The Company has not employed any employees whose remuneration falls within the purviewof the limits prescribed under the provisions of Section 197 of the Companies Act 2013read with Rule 5(1) of the Companies (Appointment and Remuneration of ManagerialPersonnel) Rules 2014.

Policy on Director's Key Managerial Personnel -Appointment & Remuneration includingNomination & Remuneration Committee

The Board has framed a policy on Directors Appointment and Remuneration & dulyconstituted Nomination and Remuneration Committee pursuant to Regulation 19 of SEBI(Listing Obligations and Disclosure Requirements) Regulations 2015 and read with Section178 of the Companies Act 2013.

The policy provides for selection and appointment of Directors Senior Managementincluding KMP and their Remuneration together with criteria for determiningqualifications positive attributes and independence of a Director.

Remuneration policy for the Directors Key Managerial Personnel and other Employees hasbeen disclosed on the Company website i.e. www.mavensbiotech.com.

Details of Committee members and meetings etc. have been disclosed in the CorporateGovernance Report which forms a part of this report.

Directors Responsibility Statement

Pursuant to Section 134 (3) (c) read with Section 134 (5) of the Companies Act 2013the Board of Directors to the best of their knowledge and ability confirm that:

i. in the preparation of the annual accounts for the year ended 31st March 2019 theapplicable Indian Accounting Standards have been followed along with proper explanationrelating to material departures if any;

ii. the directors have selected such accounting policies and applied them consistentlyand made judgments and estimates that are reasonable and prudent so as to give a true andfair view of the state of affairs of the company at the end of the financial year 31stMarch 2019 and of the profit or loss of the company for the year ended on that date;

iii. the directors have taken proper and sufficient care for the maintenance ofadequate accounting records in accordance with the provisions of the Act for safeguardingthe assets of the company and for preventing and detecting fraud and other irregularities;

iv. the annual accounts have been prepared on a going concern basis;

v. the directors have laid down internal financial controls to be followed by thecompany and such internal financial controls are adequate and operating effectively;

vi. the directors have devised proper systems to ensure compliance with the provisionsof all applicable laws and that such systems were adequate and operating effectively.

Declaration of Independent Directors

The Company has received necessary declaration from each of Independent Directors underSection 149(7) of the Companies Act 2013 that they meet the criteria of independencelaid down in Section 149(6) of the Companies Act 2013 and the relevant Rule andRegulation 25 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

Committee of the Board:

The Board of Directors has following Committee

1. Audit Committee

2. Nomination & Remuneration Committee

3. Stakeholder Relationship Committee

4. Risk Management Committee

The details of the Committees along with their composition number of meetings andattendance at the meetings are provided in the Corporate Governance Report.

Statement concerning development and implementation of Risk Management Policy of theCompany

The Board of Directors of the Company has framed (constituted) a Risk ManagementCommittee to frame implement and monitor the risk management plan for the Company. TheCommittee is responsible for reviewing the risk management plan and ensuring itseffectiveness. The Committee has additional oversight in the area of financial risks andcontrols. Major risks identified by the business and functions are systematically addressthrough mitigation action on a continuing basis. The details of Committee and its terms ofreference are set out in the Corporate Governance Report forming part of the Board Report.

Number of Meeting of the Board

During the year under review 6 (Six) Meetings of the Board of Directors were held. Therelevant details including composition of the Board date of meetings attendance andcomposition of various Committees of the Board are given in the Corporate GovernanceReport which forms part of this report. The details regarding the composition of variouscommittees are also available on the Company website: www.mavensbiotech.com.

Disclosure regarding Company's policies under Companies Act. 2013 and SEBI (ListingObligations and Disclosure Requirements! Regulations 2015

The Company has framed various policies as per SEBI (Listing Obligations and DisclosureRequirements) Regulations 2015 & Companies Act 2013; viz i) Remuneration Policy forthe Directors Key Managerial Personnel and other Employees ii) Determining materialEvents Policy iii) Policy on Related Party transactions v) Whistle Blower/vigil Mechanismvi) Archival Policy for disclosure vii) Code of Conduct for Directors viii) Policy ofPreservation of Documents ix) Policy for Determining Materiality subsidiary are displayedon the website of the Company www.mavensbiotech.com.

Subsidiaries Joint Ventures and Associate Companies

The Company does not have any Subsidiary Joint venture or Associate Company.

Extract of Annual Return

Pursuant to the provisions of Section 134(3)(a) of the Companies Act 2013 Extract ofthe Annual Return for the financial year ended 31st March 2018 made under the provisionsof Section 92 (3) of the Companies Act 2013 read with Rule 12(1) of the Companies(Management and administration) Rules 2014 is given in Form No. MGT-9 as Annexure-I andthe same is available on the website of the Company www.mavensbiotech.com.

Board Evaluation

Pursuant to the provisions of the Companies Act 2013and Listing Regulations 17 of theSEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 the Board hascarried out an Annual Performance evaluation of its own performance the Directorsindividually as well as the evaluation of the working of its various Committees.

A separate exercise was carried out to evaluate the performance of individual Directorsincluding the Chairman of the Board who were evaluated on parameters such as level ofengagement and contribution independence of judgment safeguarding the interest of theCompany and its minority shareholders etc.

The performance evaluation of the Independent Directors was carried out by the entireBoard excluding the Directors being evaluated.

The Performance evaluation of the Chairman and Non-Independent Directors was carriedout by the Independent Directors at their separate Meeting.

The Board of Directors expressed its satisfaction with the evaluation process.

Particulars of Loans Guarantees or Investments made under Section 186 of the CompaniesAct 2013

The Company has complied with the provisions of Section186 of the Companies Act 2013in respect of investments made and outstanding at the year-end details of which are givenin the Financial Statements. There were no loans or guarantees made by the Company duringthe year under review.

Particulars of Contracts or Arrangements made with Related Parties

There were no contracts or arrangements made with related parties as defined underSection 188 of the Companies Act 2013 during the year under review and hence enclosure ofFORM AOC-2 with the Board Report is not required. The Company has developed a RelatedParty Transactions Policy for the purpose of identification and monitoring of such type oftransactions.

Internal Financial Control and their adequacy

The Company has an Internal Control System commensurate with the size scale andcomplexity of its operations. The Company has developed well-defined internal controlmechanisms and comprehensive internal audit program with the activities of the entireorganization under its ambit. Further based on the report of Internal Audit functioncorrective action are undertaken in the respective areas and thereby strengthen thecontrols. Significant audit observations and corrective actions thereon are presented tothe Audit Committee of the Board.

Corporate Governance

The Company conforms to the norms of Corporate Governance as envisaged in the ListingRegulations with the Stock Exchange. Pursuant to Regulation 34(3) read with Schedule V ofthe SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 a detailedCompliance Note on Corporate Governance together with the Auditors Certificate onCorporate Governance is annexed to this report.

Management Discussion and Analysis Report

The Management Discussion and Analysis Report for the year under review as stipulatedunder the Securities and Exchange Board of India (Listing Obligations and DisclosureRequirements) Regulations 2015 ("Listing Regulations") are given in a separatesection and forms part of the Annual Report.

Material Changes and Commitments if any affecting the financial position of theCompany occurred between the ends of the financial year to which this financial statementrelates and the date of the report

There are no material changes and commitments affecting the financial position of theCompany occurred between ends of the financial year to which this financial statementrelates on the date of this report.

Conservation of Energy Technology Absorption Foreign Exchange Earnings and Outgo

The provisions of Section 134(m) of the Companies Act 2013 read with Rule 8(3) of theCompanies (Accounts) Rules 2014 do not apply to our Company.

Conservation of Energy : NIL
Technology Absorption : NIL
Foreign exchange earnings and out go : NIL

Details of significant and material orders passed by the Regulators or Courts orTribunals impacting the Going Concern status and Company's operation in future

There are no significant and material orders issued against the Company by anyregulating authority or court or tribunal affecting the going concern status and Company'soperation in future. Hence disclosure pursuant to Rule 8 (5) (vii) of Companies(Accounts) Rules 2014 is not required.

Auditors & Auditors Observations

The matter related to Auditors and their Reports are as under:

1. Statutory Auditor and their Report:

As per the requirements of Section 139(2) of the Companies Act 2013 and the Companies(Audit and Auditors) Rules 2014 the Board of Directors in their meeting held on 12thAugust 2019 on the recommendation of the Audit Committee re-appointed M/s. KSA &Co. Chartered Accountant (Registration No.: 003822C) as the Statutory Auditors of thecompany to hold the office from the conclusion of this 37th Annual General Meeting (AGM)until the conclusion of 41st Annual General Meeting (AGM) subject to approval of themembers. The remuneration to M/s. KSA & Co. for the years 2019-20 to 2022-23 is fixedat Rs. 65000/- (Rupees Sixty Five thousand only) per year plus reimbursement of out ofpocket expenses applicable taxes and other certifications." as set out in theOrdinary Resolution AGM Notice for the aforesaid services to be rendered by them.

Statutory Auditor has given their consent to act as the Auditors of the Company and hasconfirmed that the said appointment if made will be in accordance with the conditionsprescribed under Sections 139 and 141 of the Act.

Explanations or Comments on Qualifications Reservations or Adverse Remarks orDisclaimers made by the Statutory Auditors in their Report:

The Report given by M/s. KSA & Co. (FRN: 003822C) Statutory Auditors of theCompany for the Financial Statements for the year ended 31st March 2019 read withexplanatory notes thereon do not call for any explanation or comments from the Board underSection 134(3) of the Companies Act 2013. The remarks if any made by the Auditors intheir Report are properly explained in the Note no 22 of the Financial Statement.

2. Secretarial Auditors and their Report:

The members of Board has appointed M/s. Kavita Thaker Practicing Company Secretary toconduct Secretarial Audit of the Company for the financial year 2018-19 at their meetingon 13th February 2019 as required under Section 204 of the Companies Act 2013read with Companies (Appointment and Remuneration of Managerial Personnel) Rules 2014.

The report of the Secretarial Auditors in Form MR-3 is enclosed as Annexure-II to thisreport.

The report confirms that the Company had complied with the statutory provisions listedunder Form MR -3 and the Company also has proper board processes and compliance mechanism.

The report contains qualifications reservation or adverse remark for which furthercomments or explanations are provided below:

The Company has not appointed the Whole Time Director as Key Managerial Personnelpursuant to Section 203 of the Act and Rules made there under.

Explanations or Comments on Qualifications Reservations or Adverse Remarks orDisclaimers made by the Secretarial Auditors in their Report:

Company has appointed Mr. Kuldeep Doshi as Whole Time Director on 11/04/2019.

3. Internal Auditor:

The Members of Board has appointed M/s. Bhutoria & Associates (FRN 329621E)Chartered Accountant as Internal Auditors of the Company for Financial Year 2018-19 attheir meeting on 13th February 2019 under provisions of Section 138 of theCompanies Act 2013 read with Rule 13 of the Companies (Accounts) Rules 2014 asrecommended by Audit Committee.

The Suggestions made by the Internal Auditor in their Report were properly implemented.

Human Resources

Human Resources Development envisages the growth of the individual in tandem with theorganization. It also aims at the up-liftment of the individual by ensuring an enablingenvironment to develop capabilities and to optimize performance. Your Directors want toplace on record their appreciation for the contribution made by employees at all levelswho through their steadfastness solidarity and with their cooperation and support havemade it possible for the Company to achieve its current status.

The Company on its part would endeavor to tap individual talents and through variousinitiatives ingrain in our human resources a sense of job satisfaction that would withtime percolates down the line. It is also the endeavor of the Company to create in itsemployees a sense of belonging and an environment that promotes openness creativity andinnovation.

All the manpower initiatives including training meetings and brainstorming sessionsare implemented with the aim of maximizing productivity and aligning organizational needsemployee's aspirations.

Listing of Securities

The Equity Shares of your Company are listed with The Calcutta Stock Exchange (CSE)Limited. Listing fees has been paid to The Calcutta Stock Exchange Ltd. in pursuance toRegulation 14 of the Listing Regulation.

Shares

The Authorized Share capital and the paid up Equity Share Capital have remainedunchanged during the year under review. The Company has neither issued shares &Securities or any other instruments nor any corporate benefits during the year underreview.

1. The Company has not bought back any of its securities during the year under review.

2. The Company has not issued any Sweat Equity Shares during the year under review.

3. No Bonus Shares were issued during the year under review.

4. The Company has not provided any Stock Option Scheme to the employees.

Details of policy developed and implemented by the Company on its Corporate SocialResponsibility Initiatives

Since the Company does not developed and implemented any Corporate SocialResponsibility initiatives as the said provisions are not applicable to the Company.

Additional Information to Shareholders

All important and pertinent investor information such as financial results investorpresentations press releases are made available on the Company's website i.e.www.mavensbiotech.com on a regular basis.

Code of Conduct

As prescribed under Listing Regulation a declaration signed by the Non- ExecutiveIndependent Director affirming compliance with the Code of Conduct by the Directors andSenior Management Personnel of the Company for the financial year 2018-19 forms part ofthe Governance Report.

Reporting of Frauds

During the year under review the Statutory Auditors and Secretarial Auditors have notreported to the Audit Committee and / or Board any instances of fraud committed in theCompany by its officers or employees under Section 143(12) of the Companies Act 2013.

Vigil Mechanism/ Whistle Blower Policy

Your company is committed to highest standards of ethical moral and legal businessconduct. Accordingly the Board of Directors have formulated a Whistle Blower Policy whichis in compliance with the provisions of Section 177(10) of the Companies Act 2013 andRegulation 22 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations2015. The policy provides for a framework and process whereby concerns can be raised byits employees against any kind of discrimination harassment victimization or any otherunfair practice being adopted against them. These have been outlined in the CorporateGovernance Report which forms part of this report.

Disclosure under The Sexual Harassment of Woman at Workplace (Prevention Prohibitionand Redressal) Act 2013

The Company has in place an Anti-Sexual Harassment Policy in line with the requirementsof The Sexual Harassment of Women at the Workplace (Prevention Prohibition &Redressal) Act 2013.

Internal Complaints Committee (ICC) has been set up to redress complaints receivedregarding sexual harassment. All employees (permanent contractual temporary trainees)are covered under this policy.

The following is a summary of sexual harassment complaints received and disposed offduring the year 2018-19.

No of complaints received : Nil
No of complaints disposed off : Nil

Acknowledgement

The Directors wish to place on record their appreciation for the contributions made bythe employees at all levels whose continued commitment and dedication helped the Companyachieve better results. The Directors also wish to thank customers bankers Central andState Governments for their continued support. Finally your directors would like toexpress their sincere & whole-hearted gratitude to all of you for your faith in us andyour Co-operation & never failing support.

By Order of the Board
For Mavens Biotech Limited
Kuldeep Doshi Vinod Kumar Jha
(Whole Time Director) (Director)
(DIN: 7116760) (DIN: 07799924)
Regd. Office : Room No. 407 4th Floor PremisesNo.4
Clive Row Kolkata-700001
CIN : L17297WB1981PLC034226
Email : investors@mavensbiotech.com
Website : www.mavensbiotech.com
Date : 12th August 2019

.